[Federal Register: December 30, 2009 (Volume 74, Number 249)]
[Proposed Rules]
[Page 69040-69042]
[DOCID:fr30de09-14]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. FAA-2009-1224; Directorate Identifier 2009-NM-118-AD]
RIN 2120-AA64

Airworthiness Directives; The Boeing Company Model 737-200, -300,
-400, and -500 Series Airplanes

AGENCY: Federal Aviation Administration (FAA), Department of
Transportation (DOT).

ACTION: Notice of proposed rulemaking (NPRM).

-----------------------------------------------------------------------

SUMMARY: The FAA proposes to supersede an existing airworthiness
directive (AD) that applies to certain Model 737-300, -400, and -500
series airplanes. The existing AD currently requires an inspection to
determine the manufacturer and manufacture date of the oxygen masks in
the passenger service unit and the lavatory and attendant box
assemblies, corrective action if necessary, and other specified action.
This proposed AD would expand the applicability in the existing AD.
This AD results from a determination indicating that additional
airplanes may be subject to the identified unsafe condition. We are
proposing this AD to prevent the in-line flow indicators of the
passenger oxygen masks from fracturing and separating, which could
inhibit oxygen flow to the masks and consequently result in exposure of
the passengers and cabin attendants to hypoxia following a
depressurization event.

DATES: We must receive comments on this proposed AD by February 16,
2010.

ADDRESSES: You may send comments by any of the following methods:
     Federal eRulemaking Portal: Go to http://
www.regulations.gov. Follow the instructions for submitting comments.
     Fax:<PHONE_NUMBER>.
     Mail: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590.
     Hand Delivery: U.S. Department of Transportation, Docket
Operations, M-30, West Building Ground Floor, Room W12-140, 1200 New
Jersey Avenue, SE., Washington, DC 20590, between 9 a.m. and 5 p.m.,
Monday through Friday, except Federal holidays.
    For service information identified in this proposed AD, contact
Boeing Commercial Airplanes, Attention: Data & Services Management, P.
O. Box 3707,

MC 2H-65, Seattle, Washington 98124-2207; telephone<PHONE_NUMBER>,
extension 1, fax<PHONE_NUMBER>; e-mail<EMAIL_ADDRESS>Internet
https://www.myboeingfleet.com. You may review copies of the referenced
service information at the FAA, Transport Airplane Directorate, 1601
Lind Avenue, SW., Renton, Washington. For information on the
availability of this material at the FAA, call<PHONE_NUMBER> or 425-227-
1152.

Examining the AD Docket

    You may examine the AD docket on the Internet at http://
www.regulations.gov; or in person at the Docket Management Facility
between 9 a.m. and 5 p.m., Monday through Friday, except Federal
holidays. The AD docket contains this proposed AD, the regulatory
evaluation, any comments received, and other information. The street
address for the Docket Office (telephone<PHONE_NUMBER>) is in the
ADDRESSES section. Comments will be available in the AD docket shortly
after receipt.

FOR FURTHER INFORMATION CONTACT: Robert Hettman, Aerospace Engineer,
Cabin Safety and Environmental Systems Branch, ANM-150S, FAA, Seattle
Aircraft Certification Office, 1601 Lind Avenue, SW., Renton,
Washington 98057-3356; telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Comments Invited

    We invite you to send any written relevant data, views, or
arguments about this proposed AD. Send your comments to an address
listed under the ADDRESSES section. Include ``Docket No. FAA-2009-1224;
Directorate Identifier 2009-NM-118-AD'' at the beginning of your
comments. We specifically invite comments on the overall regulatory,
economic, environmental, and energy aspects of this proposed AD. We
will consider all comments received by the closing date and may amend
this proposed AD because of those comments.
    We will post all comments we receive, without change, to http://
www.regulations.gov, including any personal information you provide. We
will also post a report summarizing each substantive verbal contact we
receive about this proposed AD.

Discussion

    On March 9, 2008, we issued AD 2008-06-24, Amendment 39-15436 (73
FR 14666, March 19, 2008), for certain Model 737-300, -400, and -500
series airplanes. That AD requires an inspection to determine the
manufacturer and manufacture date of the oxygen masks in the passenger
service unit and the lavatory and attendant box assemblies, corrective
action if necessary, and other specified actions. That AD resulted from
a report that several passenger masks with broken in-line flow
indicators were found following a mask deployment. We issued that AD to
prevent the in-line flow indicators of the passenger oxygen masks from
fracturing and separating, which could inhibit oxygen flow to the masks
and consequently result in exposure of the passengers and cabin
attendants to hypoxia following a depressurization event.

Actions Since Existing AD Was Issued

    Since we issued AD 2008-06-24, we have determined that the oxygen
masks on the affected Model 737-300, -400, and -500 series airplanes
have the same flow indicators as those installed on certain Model 737-
200 series airplanes; therefore, Model 737-200 series airplanes may be
also subject to the identified unsafe condition.

Relevant Service Information

    We have reviewed Boeing Special Attention Service Bulletin 737-35-
1099, Revision 1, dated April 23, 2009. The specified actions are
essentially identical to those specified in Boeing Special Attention
Service Bulletin 737-35-1099, dated April 9, 2007 (which we cited in
the existing AD). Revision 1 of Boeing Special Attention Service
Bulletin 737-35-1099 expands the effectivity of the service bulletin by
adding Model 737-200 series airplanes that may have been delivered with
B/E Aerospace oxygen assemblies, identified in B/E Aerospace Service
Bulletin 174080-35-01, before January 1, 2002, and that have had the
oxygen mask assemblies replaced with assemblies manufactured between
January 1, 2002, and March 1, 2006. B/E Aerospace Service Bulletin
174080-35-01 was referred to in the existing AD as an additional source
of guidance for modifying the oxygen mask assembly.

FAA's Determination and Requirements of the Proposed AD

    We have evaluated all pertinent information and identified an
unsafe condition that is likely to develop on other products of the
same type design. For this reason, we are proposing this AD, which
would supersede AD 2008-06-24 and would retain the requirements of the
existing AD. This proposed AD would expand the applicability to include
Model 737-200 series airplanes.

Costs of Compliance

    There are about 1,981 airplanes of the affected design in the
worldwide fleet. This proposed AD would affect about 666 airplanes of
U.S. registry.
    The actions that are required by AD 2008-06-24 and retained in this
proposed AD affect about 646 airplanes of U.S. registry. The required
actions take about 16 work hours per airplane, for an average of 180
oxygen masks per airplane distributed in about 45 PSUs/oxygen boxes, at
an average labor rate of $80 per work hour. Required parts cost about
$6 per oxygen mask, or $1,080 per airplane. Based on these figures, the
estimated cost of the existing AD for U.S. operators is $1,524,560, or
$2,360 per airplane.
    This proposed AD would be applicable to approximately 20 additional
airplanes. Based on the figures discussed above, we estimate the costs
for the additional airplanes imposed by this proposed AD on U.S.
operators to be $47,200, or $2,360 per airplane. This figure is based
on assumptions that no operator of these additional airplanes has yet
done any of the proposed requirements of this AD, and that no operator
would do those actions in the future if this AD were not adopted.

Authority for This Rulemaking

    Title 49 of the United States Code specifies the FAA's authority to
issue rules on aviation safety. Subtitle I, Section 106, describes the
authority of the FAA Administrator. Subtitle VII, Aviation Programs,
describes in more detail the scope of the Agency's authority.
    We are issuing this rulemaking under the authority described in
Subtitle VII, Part A, Subpart III, Section 44701, ``General
requirements.'' Under that section, Congress charges the FAA with
promoting safe flight of civil aircraft in air commerce by prescribing
regulations for practices, methods, and procedures the Administrator
finds necessary for safety in air commerce. This regulation is within
the scope of that authority because it addresses an unsafe condition
that is likely to exist or develop on products identified in this
rulemaking action.

Regulatory Findings

    We have determined that this proposed AD would not have federalism
implications under Executive Order 13132. This proposed AD would not
have a substantial direct effect on the States, on the relationship
between the national Government and the States, or on the distribution
of power and

responsibilities among the various levels of government.
    For the reasons discussed above, I certify that the proposed
regulation:
    1. Is not a ``significant regulatory action'' under Executive Order
12866;
    2. Is not a ``significant rule'' under the DOT Regulatory Policies
and Procedures (44 FR 11034, February 26, 1979); and
    3. Will not have a significant economic impact, positive or
negative, on a substantial number of small entities under the criteria
of the Regulatory Flexibility Act.
    We prepared a regulatory evaluation of the estimated costs to
comply with this proposed AD and placed it in the AD docket. See the
ADDRESSES section for a location to examine the regulatory evaluation.

List of Subjects in 14 CFR Part 39

    Air transportation, Aircraft, Aviation safety, Incorporation by
reference, Safety.

The Proposed Amendment

    Accordingly, under the authority delegated to me by the
Administrator, the FAA proposes to amend 14 CFR part 39 as follows:

PART 39--AIRWORTHINESS DIRECTIVES

    1. The authority citation for part 39 continues to read as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701.

Sec.  39.13  [Amended]

    2. The FAA amends Sec.  39.13 by removing Amendment 39-15436 (73 FR
14666, March 19, 2008) and adding the following new AD:

The Boeing Company: Docket No. FAA-2009-1224; Directorate Identifier
2009-NM-118-AD.

Comments Due Date

    (a) The FAA must receive comments on this AD action by February
16, 2010.

Affected ADs

    (b) This AD supersedes AD 2008-06-24, Amendment 39-15436.

Applicability

    (c) This AD applies to The Boeing Company Model 737-200, -300, -
400, and -500 series airplanes, certificated in any category; as
identified in Boeing Special Attention Service Bulletin 737-35-1099,
Revision 1, dated April 23, 2009.

Subject

    (d) Air Transport Association (ATA) of America Code 35: Oxygen.

Unsafe Condition

    (e) The existing AD results from a report of a sudden decrease
in cabin pressure and deployment of the passenger oxygen mask
assemblies; several masks had broken in-line flow indicators. The
Federal Aviation Administration is issuing this AD to prevent the
in-line flow indicators of the passenger oxygen masks from
fracturing and separating, which could inhibit oxygen flow to the
masks and consequently result in exposure of the passengers and
cabin attendants to hypoxia following a depressurization event.

Compliance

    (f) You are responsible for having the actions required by this
AD performed within the compliance times specified, unless the
actions have already been done.

Restatement of Requirements of AD 2008-06-24, with New Service
Information

Inspection and Related Investigative/Corrective Actions if
Necessary

    (g) For airplanes identified in Boeing Special Attention Service
Bulletin 737-35-1099, dated April 9, 2007: Within 60 months after
April 23, 2008 (the effective date of AD 2008-06-24), do a general
visual inspection to determine the manufacturer and manufacture date
of the oxygen masks in the passenger service unit and the lavatory
and attendant box assemblies, and do the applicable corrective
action and other specified action, by accomplishing all of the
applicable actions specified in the Accomplishment Instructions of
Boeing Special Attention Service Bulletin 737-35-1099, dated April
9, 2007; or Revision 1, dated April 23, 2009; except where the
service bulletin specifies repairing the oxygen mask assembly,
replace it with a new or modified oxygen mask assembly having an
improved flow indicator. The corrective action and other specified
action must be done before further flight. As of the effective date
of this AD, use only Revision 1 of Boeing Special Attention Service
Bulletin 737-35-1099.

New Requirements of This AD

Inspection and Related Investigative/Corrective Actions if
Necessary

    (h) For airplanes other than those identified in paragraph (g)
of this AD: Within 60 months after the effective date of this AD, do
a general visual inspection to determine the manufacturer and
manufacture date of the oxygen masks in the passenger service unit
and the lavatory and attendant box assemblies, and do the applicable
corrective action and other specified action, by accomplishing all
of the applicable actions specified in the Accomplishment
Instructions of Boeing Special Attention Service Bulletin 737-35-
1099, Revision 1, dated April 23, 2009; except where the service
bulletin specifies repairing the oxygen mask assembly, replace it
with a new or modified oxygen mask assembly having an improved flow
indicator. The corrective action and other specified action must be
done before further flight.

    Note 1: Boeing Special Attention Service Bulletin 737-35-1099,
dated April 9, 2007; and Revision 1, dated April 23, 2009; refer to
B/E Aerospace Service Bulletin 174080-35-01, dated February 6, 2006;
Revision 1, dated May 1, 2006; and Revision 2, dated May 28, 2008;
as additional sources of guidance for modifying the oxygen mask
assembly by replacing the flow indicator with an improved flow
indicator.

Parts Installation

    (i) As of the effective date of this AD, no person may install a
B/E Aerospace oxygen mask assembly having a part number in the
174080 series or 174095 series with a manufacturing date after
January 1, 2002, and before March 1, 2006, on any airplane, unless
it has been modified in accordance with the requirements of
paragraph (g) or (h) of this AD.

Credit for Actions Done In Accordance With Previous Issue of the
Service Bulletin

    (j) Actions done before the effective date of this AD, in
accordance with Boeing Special Attention Service Bulletin 737-35-
1099, dated April 9, 2007, are acceptable for compliance with the
requirements of paragraph (g) of this AD.

Alternative Methods of Compliance (AMOCs)

    (k)(1) The Manager, Seattle Aircraft Certification Office (ACO),
FAA, has the authority to approve AMOCs for this AD, if requested
using the procedures found in 14 CFR 39.19. Send information to
ATTN: Robert Hettman, Aerospace Engineer, Cabin Safety and
Environmental Systems Branch, ANM-150S, FAA, Seattle Aircraft
Certification Office, 1601 Lind Avenue, SW., Renton, Washington
98057-3356; telephone<PHONE_NUMBER>; fax<PHONE_NUMBER>. Or, e-mail
information to<EMAIL_ADDRESS>    (2) To request a different method of compliance or a different
compliance time for this AD, follow the procedures in 14 CFR 39.19.
Before using any approved AMOC on any airplane to which the AMOC
applies, notify your principal maintenance inspector (PMI) or
principal avionics inspector (PAI), as appropriate, or lacking a
principal inspector, your local Flight Standards District Office.
The AMOC approval letter must specifically reference this AD.
    (3) An AMOC that provides an acceptable level of safety may be
used for any repair required by this AD, if it is approved by an
Authorized Representative for the Boeing Commercial Airplanes
Delegation Option Authorization Organization who has been authorized
by the Manager, Seattle ACO, to make those findings. For a repair
method to be approved, the repair must meet the certification basis
of the airplane.

    Issued in Renton, Washington, on December 21, 2009.
Ali Bahrami,
Manager, Transport Airplane Directorate, Aircraft Certification
Service.
[FR Doc. E9-30902 Filed 12-29-09; 8:45 am]

BILLING CODE 4910-13-P


[Federal Register Volume 87, Number 144 (Thursday, July 28, 2022)]
[Notices]
[Pages 45334-45335]
[FR Doc No: 2022-16166]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-D-1253]

Laser-Assisted In Situ Keratomileusis Lasers--Patient Labeling
Recommendations; Draft Guidance for Industry and Food and Drug
Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
the availability of the draft guidance entitled ``Laser-Assisted In
Situ Keratomileusis (LASIK) Lasers--Patient Labeling Recommendations.''
This draft guidance recommends content and formatting for patient
labeling information for LASIK devices. FDA is issuing this guidance to
help ensure that physicians can share and patients can understand
information on the benefits and risks of these devices. The
recommendations are being made based on concerns that some patients are
not receiving and/or understanding information regarding the benefits
and risks of LASIK devices. This draft guidance is not final nor is it
for implementation at this time.

DATES: Submit either electronic or written comments on the draft
guidance by October 26, 2022 to ensure that the Agency considers your
comment on this draft guidance before it begins work on the final
version of the guidance.

ADDRESSES: You may submit comments on any guidance at any time as
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2022-D-1253 for ``Laser-Assisted In Situ Keratomileusis (LASIK)
Lasers--Patient Labeling Recommendations.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the draft guidance document entitled
``Laser-Assisted In Situ Keratomileusis (LASIK) Lasers--Patient
Labeling Recommendations'' to the Office of Policy, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send
one self-

addressed adhesive label to assist that office in processing your
request.

FOR FURTHER INFORMATION CONTACT: Bradley Cunningham, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 1414, Silver Spring, MD 20993-0002, 301-
796-6484.

SUPPLEMENTARY INFORMATION:

I. Background

    LASIK is currently one of the most commonly performed elective
procedures in the world, as well as the most popular form of refractive
surgery that patients choose to correct common vision problems such as
nearsightedness, farsightedness, and astigmatism.\1\ On April 25, 2008,
FDA convened its Ophthalmic Devices Panel of the Medical Devices
Advisory Committee to discuss recommendations for modifications to
patient labeling of excimer lasers for LASIK as well as other LASIK-
related activities. Since the LASIK Advisory Committee meeting, FDA has
continued to gather new information pertaining to risks associated with
LASIK. This draft guidance recommends content and formatting for
patient labeling information for LASIK devices. FDA is issuing this
guidance to help ensure that physicians can share and patients can
understand information on the benefits and risks of these devices. The
recommendations are being made based on concerns the Agency has
received regarding patients not receiving and/or understanding key
information regarding the benefits and risks of LASIK devices. These
labeling recommendations are intended to enhance, but not replace, the
physician-patient discussion of the benefits and risks of LASIK devices
that uniquely pertain to individual patients.
---------------------------------------------------------------------------

    \1\ Vitale, S., Cotch, M.F., Sperduto, R., Ellwein L., ``Costs
of Refractive Correction of Distance Vision Impairment in the United
States, 1999-2002,'' Ophthalmology, vol. 113, pp. 2163-2170, 2006.
---------------------------------------------------------------------------

    This draft guidance is being issued consistent with FDA's good
guidance practices regulation (21 CFR 10.115). The draft guidance, when
finalized, will represent the current thinking of FDA on ``Laser-
Assisted In Situ Keratomileusis (LASIK) Lasers--Patient Labeling
Recommendations.'' It does not establish any rights for any person and
is not binding on FDA or the public. You can use an alternative
approach if it satisfies the requirements of the applicable statutes
and regulations.

II. Electronic Access

    Persons interested in obtaining a copy of the draft guidance may do
so by downloading an electronic copy from the internet. A search
capability for all Center for Devices and Radiological Health guidance
documents is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This guidance document is also
available at https://www.regulations.gov or https://www.fda.gov/regulatory-information/search-fda-guidance-documents. Persons unable to
download an electronic copy of ``Laser-Assisted In Situ Keratomileusis
(LASIK) Lasers--Patient Labeling Recommendations'' may send an email
request to [email protected] to receive an electronic copy of
the document. Please use the document number 16053 and complete title
to identify the guidance you are requesting.

III. Paperwork Reduction Act of 1995

    While this guidance contains no new collection of information, it
does refer to previously approved FDA collections of information.
Therefore, clearance by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3521) is not
required for this guidance. The previously approved collections of
information are subject to review by OMB under the PRA. The collections
of information in the following FDA regulations have been approved by
OMB as listed in the following table:

------------------------------------------------------------------------
                                                            OMB Control
            21 CFR part                     Topic               No.
------------------------------------------------------------------------
814, subparts A through E.........  Premarket approval..       0910-0231
800, 801, and 809.................  Medical Device             0910-0485
                                     Labeling
                                     Regulations.
------------------------------------------------------------------------

    Dated: July 22, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-16166 Filed 7-27-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register Volume 83, Number 57 (Friday, March 23, 2018)]
[Notices]
[Pages 12743-12744]
[FR Doc No: 2018-05952]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings #1

    Take notice that the Commission received the following electric
corporate filings:

    Docket Numbers: EC18-55-000.
    Applicants: EAM Nelson Holding, LLC, Entergy Nuclear Generation
Company, Entergy Nuclear Indian Point 2, LLC, Entergy Nuclear Indian
Point 3, LLC, Entergy Nuclear Palisades, LLC, Entergy Nuclear Power
Marketing, LLC, Entergy Power, LLC, EWO Marketing, LLC, RS Cogen, LLC.
    Description: Supplement to February 8, 2018 Joint application of
EAM Nelson Holding, LLC, et al., for FPA Section 203 authorization.
    Filed Date: 3/15/18.
    Accession Number: 20180315-5157.
    Comments Due: 5 p.m. ET 3/26/18.

    Docket Numbers: EC18-71-000.
    Applicants: NorthWestern Corporation, NJR Clean Energy Ventures II
Corporation.
    Description: Application of NorthWestern Corporation, et al. for
FPA Section 203 Authorization.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5134.
    Comments Due: 5 p.m. ET 4/6/18.

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER18-1-003.
    Applicants: California Independent System Operator Corporation.
    Description: Compliance filing: 2018-03-16 Reliability Services
Initiative Phase 1b and Phase 2 Compliance to be effective 3/16/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5077.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER10-2063-002.
    Applicants: Otter Tail Power Company.
    Description: Errata to December 28, 2017 Triennial MBR Report for
Central Region of Otter Tail Power Company.
    Filed Date: 3/15/18.

    Accession Number: 20180315-5148.
    Comments Due: 5 p.m. ET 4/5/18.

    Docket Numbers: ER16-120-006.
    Applicants: New York Independent System Operator, Inc.
    Description: Compliance filing: Amendment of 1/16/18 RMR compliance
filing to be effective 10/20/2015.
    Filed Date: 3/15/18.
    Accession Number: 20180315-5140.
    Comments Due: 5 p.m. ET 4/5/18.

    Docket Numbers: ER18-815-002.
    Applicants: PJM Interconnection, L.L.C.
    Description: Tariff Amendment: Second Errata Filing in Docket No.
ER18-815 RE: Regulation Resource Credit to be effective 4/9/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5044.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1117-000.
    Applicants: Northern States Power Company, a Minnesota corporation,
Northern States Power Company, a Wisconsin corporation.
    Description: Sec.  205(d) Rate Filing: 2018 Interchange Agreement
Annual Filing to be effective 1/1/2018.
    Filed Date: 3/15/18.
    Accession Number: 20180315-5144.
    Comments Due: 5 p.m. ET 4/5/18.

    Docket Numbers: ER18-1128-000.
    Applicants: Portland General Electric Company.
    Description: Sec.  205(d) Rate Filing: Amended NTTG Funding
Agreement to be effective 5/15/2016.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5039.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1130-000.
    Applicants: PJM Interconnection, L.L.C., Mid-Atlantic Interstate
Transmission, LLC, American Transmission Systems, Incorporation.
    Description: Sec.  205(d) Rate Filing: MAIT and ATSI submit Seven
ECSAs SA Nos. 4866, 4867, 4868, 4887, 4888, 4889, 4925 to be effective
5/16/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5041.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1131-000.
    Applicants: PJM Interconnection, L.L.C.
    Description: Sec.  205(d) Rate Filing: Revisions to OATT Sch 12-
Appx A re: RTEP Projects Approved by Board in Feb. 2018 to be effective
6/14/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5043.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1132-000.
    Applicants: Public Service Company of Colorado.
    Description: Sec.  205(d) Rate Filing: PSC-BLDR-SHGDIA & Dist.
Wheeling Agrmts-Multi-0.0.0 to be effective 3/17/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5045.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1134-000.
    Applicants: Flat Rock Windpower LLC.
    Description: Sec.  205(d) Rate Filing: Second Revised MBR Tariff to
be effective 3/17/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5065.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1136-000.
    Applicants: Alabama Power Company.
    Description: Sec.  205(d) Rate Filing: RES America Developments
(Durant Bend Solar) LGIA Filing to be effective 3/5/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5081.
    Comments Due: 5 p.m. ET 4/6/18.

    Docket Numbers: ER18-1137-000.
    Applicants: Flat Rock Windpower II LLC.
    Description: Sec.  205(d) Rate Filing: Second Revised MBR Tariff to
be effective 3/17/2018.
    Filed Date: 3/16/18.
    Accession Number: 20180316-5084.
    Comments Due: 5 p.m. ET 4/6/18.

    Take notice that the Commission received the following electric
reliability filings:

    Docket Numbers: RR18-4-000.
    Applicants: North American Electric Reliability Corporation.
    Description: Petition for Approval of Amended Compliance and
Certification Committee Charter of North American Electric Reliability
Corporation.
    Filed Date: 3/15/18.
    Accession Number: 20180315-5181.
    Comments Due: 5 p.m. ET 4/5/18.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5:00
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2018-05952 Filed 3-22-18; 8:45 am]
 BILLING CODE 6717-01-P


[Federal Register: February 12, 2009 (Volume 74, Number 28)]
[Notices]
[Page 7039]
[DOCID:fr12fe09-37]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER09-553-000]

Vista Energy Marketing, LP; Supplemental Notice That Initial
Market-Based Rate Filing Includes Request for Blanket Section 204
Authorization

February 5, 2009.
    This is a supplemental notice in the above-referenced proceeding of
Vista Energy Marketing, LP's application for market-based rate
authority, with an accompanying rate tariff, noting that such
application includes a request for blanket authorization, under 18 CFR
Part 34, of future issuances of securities and assumptions of
liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street, NE.,
Washington, DC 20426, in accordance with Rules 211 and 214 of the
Commission's Rules of Practice and Procedure (18 CFR 385.211 and
385.214). Anyone filing a motion to intervene or protest must serve a
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR Part 34, of future issuances of securities and assumptions of
liability, is February 25, 2009.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://
www.ferc.gov. To facilitate electronic service, persons with Internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically should submit an original and
14 copies of the intervention or protest to the Federal Energy
Regulatory Commission, 888 First St. NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in
the Commission's eLibrary system by clicking on the appropriate link in
the above list. They are also available for review in the Commission's
Public Reference Room in Washington, DC. There is an eSubscription link
on the Web site that enables subscribers to receive e-mail notification
when a document is added to a subscribed docket(s). For assistance with
any FERC Online service, please e-mail<EMAIL_ADDRESS>or
call<PHONE_NUMBER> (toll free). For TTY, call<PHONE_NUMBER>.

Kimberly D. Bose,
Secretary.
 [FR Doc. E9-2963 Filed 2-11-09; 8:45 am]

BILLING CODE 6717-01-P